Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Omeros (OMER)

Omeros Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OMER
DateTimeSourceHeadlineSymbolCompany
14/02/202514:00Business WireOmeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem MeetingsNASDAQ:OMEROmeros Corporation
10/02/202514:00Business WireOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramNASDAQ:OMEROmeros Corporation
16/01/202514:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
16/01/202514:15Business WireOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary EndpointNASDAQ:OMEROmeros Corporation
19/12/202414:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
19/12/202414:15Business WireOmeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMANASDAQ:OMEROmeros Corporation
10/12/202413:45Business WireOmeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
02/12/202413:45Business WireOmeros Corporation Announces Upcoming Presentations at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
21/11/202414:15Business WireOmeros Corporation Provides Update on Progress Toward BLA ResubmissionNASDAQ:OMEROmeros Corporation
13/11/202421:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
13/11/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
13/11/202421:02Business WireOmeros Corporation Reports Third Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
11/11/202421:11Business WireOmeros Corporation to Announce Third Quarter Financial Results on November 13, 2024NASDAQ:OMEROmeros Corporation
24/10/202412:45Business WireFDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 GlomerulopathyNASDAQ:OMEROmeros Corporation
07/08/202420:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
07/08/202420:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
07/08/202420:02Business WireOmeros Corporation Reports Second Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
05/08/202420:02Business WireOmeros Corporation to Announce Second Quarter Financial Results on August 7, 2024NASDAQ:OMEROmeros Corporation
12/06/202420:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
07/06/202421:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
07/06/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
07/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
07/06/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
07/06/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
07/06/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
04/06/202413:00Business WireOmeros Announces Webcast Details for Annual Meeting of ShareholdersNASDAQ:OMEROmeros Corporation
03/06/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
03/06/202413:00Business WireOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028NASDAQ:OMEROmeros Corporation
15/05/202420:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
15/05/202420:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
 Showing the most relevant articles for your search:NASDAQ:OMER

Your Recent History